Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03603509 · ClinicalTrials.gov registry record · Phase 4
Gene Signatures of Influenza Vaccine Responses in Older Adults
A Phase 4 study of Influenza, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 241
- Enrollment target
- 1
- Study location
NCT03603509: Completed Phase 4 study of Influenza, sponsored by Mayo Clinic.
NCT03603509 is a Phase 4 study of Influenza that has completed, run by Mayo Clinic. The registered enrollment target is 241 participants, below the 36,802-participant average among 156 other Influenza trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03603509, a Phase 4 study of Influenza, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 241 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to better understand the immune response to the Adjuvanted Subunit flu vaccine (MF59) and the High Dose flu vaccine (HDFlu) in people 65 years of age and older. The research team will be studying why immune response diminishes as people get older in both men and women. The ultimate goal is to understand how flu immunity develops after vaccination. This information may lead to the development of more effective flu vaccines in the future.
Primary Outcome
Cytokine secretion (interferon alpha 2a) after in vitro stimulation with influenza virus
Conditions Studied
Interventions
- DRUG Fluzone High-Dose
- DRUG Fluad Vaccine
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 241 participants |
| Start Date | 2018-08-27 |
| Est. Completion | 2019-01-02 |
| Phase | Phase 4 |
What the finished NCT03603509 record still lists
NCT03603509 is an interventional study that assigns participants to a tested intervention. The registered 241 participants enrollment target is mid-sized for trials with a published cap, below the 36,802-participant average among 156 other Influenza trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 2 interventions - of which Fluzone High-Dose is the first listed.
NCT03603509 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT03603509 about?
NCT03603509 is a clinical study titled "Gene Signatures of Influenza Vaccine Responses in Older Adults". The purpose of this research study is to better understand the immune response to the Adjuvanted Subunit flu vaccine (MF59) and the High Dose flu vaccine (HDFlu) in people 65 years of age and older. The research team will be studying why immune response diminishes as people get older in both men and...
What is the current status of trial NCT03603509?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 241 participants. The study started on 2018-08-27. Estimated completion is 2019-01-02.
What conditions does trial NCT03603509 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT03603509?
The interventions under investigation include: Fluzone High-Dose (DRUG), Fluad Vaccine (DRUG).
Who is sponsoring clinical trial NCT03603509?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03603509 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03603509's enrollment target sits among peer trials
241 76th of 156 higher than 81 of 156 other Influenza trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Influenza trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults
RECRUITING · Phase 4
-
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
RECRUITING · Phase 4
-
Bone Marrow and Peripheral Blood Immune Responses Study
RECRUITING · Phase 4
-
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine
COMPLETED · Phase 4
-
A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age
COMPLETED · Phase 4
-
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01189786 · 241 participants · NA
Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection
- NCT05050383 · 241 participants · NA
DISE: Phenotyping Obstruction Patterns
- NCT05683418 · 241 participants · Phase 1
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors
- NCT07213791 · 241 participants · Phase 1
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI